Haemonetics (HAE) Misses Q4 EPS by 21c, Revenues Beat; Offers FY22 EPS Guidance Above Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high on Alphabet boost, Mideast negotiation hopes
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Haemonetics (HAE) PT Lowered to $86 at Needham & Company
May 13, 2021 1:03 PM EDTNeedham & Company analyst Mike Matson lowered the price target on Haemonetics (NYSE: HAE) to $86.00 (from $108.00) while maintaining a Buy rating.
The analyst commented, "HAE's F4Q21 revenue beat and EPS missed consensus. HAE's organic growth slowed to (13.7%) in F4Q21 vs. (5.7%)... More
Jefferies Sees Haemonetics (HAE) as Oversold Ahead of Earnings, PT Lowered $105
May 12, 2021 8:10 AM EDTJefferies analyst Anthony Petrone lowered the price target on Haemonetics (NYSE: HAE) to $105.00 (from $185.00) ahead of the F4Q earnings call scheduled for 5/13 BMO. Focus points for the call are expected to include: 1) detail/commentary on CSL's plasma supply chain shift toward Terumo; 2) future contracting implications, 3)... More
